Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety , Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea

Next Previous
Trial Profile

A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety , Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Taspoglutide (Primary) ; Pioglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms EMERGE-6; T-EMERGE-6
  • Sponsors Roche

Most Recent Events

  • 14 Apr 2016 This trial is prematurely ended in Spain (end date: 11 Jan 2011), UK (end date: 23 Nov 2010), Germany (end date: 31 Jan 2011), Poland (end date: 31 Jan 2011), Slovakia and Italy.
  • 18 Apr 2011 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
  • 15 Oct 2010 Planned end date changed from 1 Jul 2012 to 1 Dec 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top